Tea (Camellia sinensis) is one of the world's most widely consumed beverages, and the size of young buds directly influences ...

Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi ...

Researchers have identified that the precisely timed transcription of two genes named grim and reaper is responsible for the ...

Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP ...

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

Replacing APOE4 with APOE2 in adult mice rapidly reshapes brain lipids and gene expression, even after development is ...

Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Hello, and thank you for standing by. Welcome to Allogene ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...